country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-106685

Copy Link Print Information

Selenazofurin

(Synonyms: CI 935)

Selenazofurin is an antiviral compound used against influenza A and influenza B viruses. Selenazofurin shows antiviral activity in cells against Measles, Para-3, Mumps, VV, HSV-2 with the ED₅₀s of 3.7 μg/ml, 1.3 μg/ml, 8.0 μg/ml, 3.4 μg/ml, 4.3 μg/ml.

For research use only. We do not sell to patients.

CAS No.: 83705-13-9
Formula: C₉H₁₂N₂O₅Se
Molecular Weight:307.16

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Selenazofurin Chemical Structure

CAS No.: 83705-13-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	2.3 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line	[PMID: 9171883]
ACHN	IC₅₀	13.8 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma	[PMID: 9171883]
CCRF-CEM	IC₅₀	1.2 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against CCRF-CEM, human acute T-lymphoblastic leukemia Compound was tested for antiproliferative activity against CCRF-CEM, human acute T-lymphoblastic leukemia	[PMID: 9171883]
CCRF-SB	IC₅₀	1.5 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against CCRF-SB, human acute B-lymphoblastic leukemia Compound was tested for antiproliferative activity against CCRF-SB, human acute B-lymphoblastic leukemia	[PMID: 9171883]
CHO-K1	IC₅₀	0.6 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against CHO-K1, Chinese hamster ovary Compound was tested for antiproliferative activity against CHO-K1, Chinese hamster ovary	[PMID: 9171883]
HeLa	IC₅₀	7.9 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against HeLa, human cervix carcinoma Compound was tested for antiproliferative activity against HeLa, human cervix carcinoma	[PMID: 9171883]
HT-29	IC₅₀	7.7 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against HT29, human colon adenocarcinoma Compound was tested for antiproliferative activity against HT29, human colon adenocarcinoma	[PMID: 9171883]
K562	IC₅₀	0.5 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against K562, human erythroid leukemia Compound was tested for antiproliferative activity against K562, human erythroid leukemia	[PMID: 9171883]
L1210	IC₅₀	0.5 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against L1210, murine lymphocytic leukemia Compound was tested for antiproliferative activity against L1210, murine lymphocytic leukemia	[PMID: 9171883]
MOLT-4	IC₅₀	0.6 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against MOLT-4, human acute T-lymphoblastic leukemia Compound was tested for antiproliferative activity against MOLT-4, human acute T-lymphoblastic leukemia	[PMID: 9171883]
Raji	IC₅₀	1.6 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against Raji, human Burkitt lymphoma Compound was tested for antiproliferative activity against Raji, human Burkitt lymphoma	[PMID: 9171883]
Vero	ED₅₀	1.4 x 10^-5M Compound: Selenazofurin	In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated. In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.	[PMID: 4020823]
Vero	ED₅₀	3.2 x 10^-6M Compound: Selenazofurin	In vitro antiviral activity against measles virus was evaluated. In vitro antiviral activity against measles virus was evaluated.	[PMID: 4020823]
Vero	ED₅₀	3.2 x 10^-6M Compound: Selenazofurin	In vitro antiviral activity against Parainfluenza type 3 was evaluated. In vitro antiviral activity against Parainfluenza type 3 was evaluated.	[PMID: 4020823]
Vero	ED₅₀	9.8 x 10^-6M Compound: Selenazofurin	In vitro antiviral activity against vaccinia virus was evaluated. In vitro antiviral activity against vaccinia virus was evaluated.	[PMID: 4020823]
WIL2-NS	IC₅₀	1.2 μM Compound: Selenazofurin	Compound was tested for antiproliferative activity against Wil2-NS, human splenic lymphoblastoid cells Compound was tested for antiproliferative activity against Wil2-NS, human splenic lymphoblastoid cells	[PMID: 9171883]

Chemical Information

CAS No. 83705-13-9
Molecular Weight 307.16
Formula C₉H₁₂N₂O₅Se
SMILES

O[C@H]1[C@@H](O)[C@H](C2=NC(C(N)=O)=C[Se]2)O[C@@H]1CO
Synonyms

CI 935
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. J J Kirsi, et al. Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin. Antimicrob Agents Chemother. 1984 Oct;26(4):466-75. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote